Results 321 to 330 of about 100,641 (375)

Sex‐Based Differences in Noncommunicable Diseases in Older Adults: Raising the Profile of Older Females

Journal of the American Geriatrics Society, EarlyView.
Aathmika Nandan, Joyce M. Li, Paula A. Rochon   +2 more
wiley   +1 more source

Correction: López-Manzanares et al. Real-World Use of COMT Inhibitors in the Management of Patients with Parkinson's Disease in Spain Who Present Early Motor Fluctuations: Interim Results from the REONPARK Study. <i>Brain Sci.</i> 2025, <i>15</i>, 532. [PDF]

Brain Sci
López-Manzanares L, García Caldentey J, Álvarez-Santullano MM, Vilas Rolán D, Herreros-Rodríguez J, Solano Vila B, Cerdán Sánchez M, Delgado Ballestero T, García-Ramos R, Rodríguez-Sanz A, Olivares Romero J, Blanco Ameijeiras J, Pijuan Jiménez I, Tegel Ayuela I, REONPARK Study Group.   +14 more
europepmc   +1 more source

The role of presynaptic dopaminergic imaging in acquired neurological conditions affecting basal ganglia: a systematic review. [PDF]

Front Neurol
Ardila Jurado E, Zünd-Hofer L, Brugger F, Nicastro N, Bhatia KP, Kägi G.   +5 more
europepmc   +1 more source

The Cost-Effectiveness of Opicapone Versus Entacapone as Adjuvant Therapy for Levodopa-Treated Individuals With Parkinson's Disease Experiencing End-of-Dose Motor Fluctuations. [PDF]

Parkinsons Dis
Harrison-Jones G, Green W, Bainbridge J.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease

Neurology, 2022
Background and Objectives Interindividual variability in levodopa efficacy is a challenge for the personalized treatment of Parkinson disease (PD). Gut microbiota might represent a new approach for personalized medicine.
Yi Zhang, Xiaoqin He, Chengjun Mo, Xiaoqian Liu, Jian Li, Zheng Yan, Yiwei Qian, Yi-Ting Lai, Shao-Qing Xu, Xiaodong Yang, Qin Xiao   +10 more
semanticscholar   +1 more source

In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery

Pharmaceutical development and technology (Print), 2020
Parkinson’s disease (PD) is a neurodegenerative disease which is characterized by the loss of dopaminergic neurons in the brain. Levodopa is the drug of choice in the treatment of PD but it exhibits low oral bioavailability (30%) and very low brain ...
S. Arısoy, Ozgun Sayiner, T. Çomoğlu, D. Onal, O. Atalay, B. Pehli̇vanoğlu   +5 more
semanticscholar   +1 more source

Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease

Expert Opinion on Drug Metabolism & Toxicology, 2020
Introduction: Parkinson’s disease is a chronic, neurodegenerative disease entity with heterogeneous features and course. Levodopa is the most efficacious dopamine substituting drug.
T. Müller
semanticscholar   +1 more source

Levodopa‐induced dyskinesias

Movement Disorders, 2007
AbstractLevodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management. The three primary clinical syndromes are OFF‐period dystonia, peak‐dose dyskinesia, and diphasic dyskinesia. Several other forms
FABBRINI, Giovanni, Jonathan M. Brotchie, Francisco Grandas, Masahiro Nomoto, Christopher G. Goetz   +4 more
openaire   +3 more sources